Last reviewed · How we verify
salvadora
salvadora is a Small molecule drug developed by Ajman University. It is currently in Phase 1 development. Also known as: Miswak.
Salvadora is a genus of flowering plants in the family Salvadoraceae, and it is also the name of a type of plant-based stick used as a toothbrush, known as Miswak. Clinical trials have studied the effect of brushing with Miswak sticks on dental health conditions such as plaque, dental caries, and oral malodor.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | salvadora |
|---|---|
| Also known as | Miswak |
| Sponsor | Ajman University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Miswak (Salvadora Persica) Versus a Toothbrush in Plaque Removal (NA)
- The Effect of Salvadora Persica (Miswak) Compared to Fluoridated Toothpaste on Children's Teeth Diagnosed With Molar-Incisor Hypomineralization (MIH): A Randomized Clinical Trial (NA)
- The Effects of Green Tea and Salvadora Persica L. in Patients With Gingivitis (PHASE2)
- Antiplaque Efficacy of Two Novel Commercially Available Herbal Toothpastes. (PHASE1)
- Comparative Clinical Effects of Salvadora Persica Oral Rinse And A Phenolic Commercial Mouth Wash On Human Oral Health (NA)
- Effectiveness of Salvadora Persica Miswak in Improving Plaque Control and Gingival Health (NA)
- The Effect of Brushing With Salvadorapersica (Miswak) Sticks on Salivary Streptococcus Mutants and Plaque Level in Children: A Clinical Trial (PHASE3)
- Anti Plaque Efficacy of Salvadora Persica L. and Green Tea Mouthwash (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- salvadora CI brief — competitive landscape report
- salvadora updates RSS · CI watch RSS
- Ajman University portfolio CI
Frequently asked questions about salvadora
What is salvadora?
Who makes salvadora?
Is salvadora also known as anything else?
What development phase is salvadora in?
Related
- Manufacturer: Ajman University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Miswak
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing